Stock Track | Pacira Pharmaceuticals Plummets 5.57% Intraday After Q1 Earnings Decline and Maintained Forecast

Stock Track05-01

Pacira Pharmaceuticals (PCRX) saw its shares plummet 5.57% intraday on Friday, following the release of its first-quarter earnings report.

The company reported Q1 non-GAAP earnings of $0.60 per diluted share, down from $0.62 a year earlier, despite beating analyst expectations of $0.55. Revenue for the quarter rose to $177.4 million from $168.9 million a year ago, also surpassing estimates of $171.8 million.

However, investors reacted negatively as earnings declined year-over-year, and the company maintained its 2026 revenue forecast of $745 million to $770 million without an upward revision, potentially disappointing some market participants.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1196806264?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-01 22:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1196806264","market":"hk","top_or_hot":-1,"title":"Stock Track | Pacira Pharmaceuticals Plummets 5.57% Intraday After Q1 Earnings Decline and Maintained Forecast","media":"Stock Track","content":"<p>Pacira Pharmaceuticals (PCRX) saw its shares plummet 5.57% intraday on Friday, following the release of its first-quarter earnings report.</p><p>The company reported Q1 non-GAAP earnings of $0.60 per diluted share, down from $0.62 a year earlier, despite beating analyst expectations of $0.55. Revenue for the quarter rose to $177.4 million from $168.9 million a year ago, also surpassing estimates of $171.8 million.</p><p>However, investors reacted negatively as earnings declined year-over-year, and the company maintained its 2026 revenue forecast of $745 million to $770 million without an upward revision, potentially disappointing some market participants.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Pacira Pharmaceuticals Plummets 5.57% Intraday After Q1 Earnings Decline and Maintained Forecast</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Pacira Pharmaceuticals Plummets 5.57% Intraday After Q1 Earnings Decline and Maintained Forecast\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-05-01 22:18</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Pacira Pharmaceuticals (PCRX) saw its shares plummet 5.57% intraday on Friday, following the release of its first-quarter earnings report.</p><p>The company reported Q1 non-GAAP earnings of $0.60 per diluted share, down from $0.62 a year earlier, despite beating analyst expectations of $0.55. Revenue for the quarter rose to $177.4 million from $168.9 million a year ago, also surpassing estimates of $171.8 million.</p><p>However, investors reacted negatively as earnings declined year-over-year, and the company maintained its 2026 revenue forecast of $745 million to $770 million without an upward revision, potentially disappointing some market participants.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PCRX","symbol_name":"Pacira Pharmaceuticals","start_time":0,"source_url":"","article_id":"1196806264","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1196806264","pubTimestamp":1777645105,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Pacira Pharmaceuticals (PCRX) saw its shares plummet 5.57% intraday on Friday, following the release of its first-quarter earnings report.The company reported Q1 non-GAAP earnings of $0.60 per...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PCRX":"Pacira Pharmaceuticals"},"translate_title":"个股追踪|Pacira制药Q1盈利下滑维持预期后盘中暴跌5.57%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PCRX":1},"content_text":"Pacira Pharmaceuticals (PCRX) saw its shares plummet 5.57% intraday on Friday, following the release of its first-quarter earnings report.The company reported Q1 non-GAAP earnings of $0.60 per diluted share, down from $0.62 a year earlier, despite beating analyst expectations of $0.55. Revenue for the quarter rose to $177.4 million from $168.9 million a year ago, also surpassing estimates of $171.8 million.However, investors reacted negatively as earnings declined year-over-year, and the company maintained its 2026 revenue forecast of $745 million to $770 million without an upward revision, potentially disappointing some market participants.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1196806264","isCrawlerRequest":true}